X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
IPdR (ropidoxuridine) is a radiation sensitizing agent given during radiotherapy. It iscurrently being investigated for the treatment of IDH-wildtype glioblastoma.
Lead Product(s): Ropidoxuridine
Therapeutic Area: Oncology Product Name: IPdR
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
IPdR Prodrug (ropidoxuridine) is a radiation sensitizing agent given during radiotherapy. It iscurrently being investigated for the treatment of IDH-wildtype glioblastoma.
Lead Product(s): Ropidoxuridine
Therapeutic Area: Oncology Product Name: IPdR Prodrug
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in Glioblastoma, a type of brain tumor.
Lead Product(s): Ropidoxuridine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.
Lead Product(s): Ropidoxuridine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
Details:
The agreement aims at the formulation development and clinical batch manufacture of drug capsules of Ropidoxuridine. Ropidoxuridine is used to sensitize rapidly growing cancer cells and selective histone deacetylase inhibitors to sensitize cancer cells.
Lead Product(s): Ropidoxuridine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Iowa Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2023
Details:
IPdR (ropidoxuridine), Shuttle's lead clinical stage product candidate, is an orally available halogenated pyrimidine (5-iodo-2-pyrimidinone-2-deoxyribose) with strong cancer radiation sensitizing properties.
Lead Product(s): Ropidoxuridine,Radiation Therapy
Therapeutic Area: Oncology Product Name: IPdR
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Theradex Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Ropidoxuridine (also called IPdR), the lead clinical sensitizer drug candidate, sensitizes rapidly growing cancer cells and selective histone deacetylase (HDAC) inhibitors, to sensitize cancer cells and stimulate the immune system.
Lead Product(s): Ropidoxuridine
Therapeutic Area: Oncology Product Name: IPdR
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: TCG GreenChem
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 20, 2022
Details:
The net proceeds from this offering will fund Phase II clinical trials and IND-enabling studies of candidates, including radiation sensitizer Ropidoxuridine (IPdR) and the HDAC inhibitor small molecule technology platform, and working capital and general corporate purposes.
Lead Product(s): Ropidoxuridine
Therapeutic Area: Oncology Product Name: IPdR
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boustead Securities
Deal Size: $9.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 06, 2022
Details:
The company intends the use the net proceeds for the research and development of clinical pipeline including it's lead asset ropidoxuridine (IPdR), and for other general and corporate purpose.
Lead Product(s): Ropidoxuridine
Therapeutic Area: Oncology Product Name: IPdR
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boustead Securities
Deal Size: $9.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
